Amara Raja Energy & Mobility Ltd. makes a corporate announcement

As of Q1 FY27, the Giga Corridor deployment is active but still in the build-out phase. ARE&M spent approximately Rs 450 Crores in Q1 FY27 against a Rs 1,700 Crores FY27 capex plan, implying a derived deployment of roughly 26.47%. The company expects approximately Rs 1,300 Crores, or about 76.47% of the annual plan, to be directed to new energy, including Giga 1, BESS, the E+ve plant and related projects. ^[1]

• The company has not disclosed the Q1 amount attributable specifically to the Giga Corridor. However, the customer qualification plant was commissioned in July 2026, BESS Giga-factory construction had commenced, and Giga 1 remained targeted for commercial production in H1 FY28. ^{[2] [3]}
• ARE&M has also stated that Rs 1,900 Crores has been infused into Amara Raja Advanced Cell Technologies to date. This is subsidiary funding and should not be treated automatically as cumulative Giga Corridor capex spent. ^[2]
• The broader Giga Corridor ambition remains a Rs 9,500 Crores investment programme in Telangana, with planned cell capacity of up to 16 GWh by FY30. ^{[4] [5]}

Debt-to-equity alignment: management has not provided a numerical debt-to-equity target for FY27. Instead, it said that leverage would be assessed case by case depending on the risk and economics of each new-energy project, while noting that the holding company could fund the programme from internal cash generation. ^[6]

The balance sheet remains conservatively leveraged: consolidated debt-to-equity was 0.03x in Q1 FY27, while consolidated net debt-to-equity was 0.01x. ^{[7] [8]} Management also cited an initial risk-capital allocation of approximately Rs 2,500 Crores as sufficient to complete the five facilities under discussion. ^[9]

Analyst read: capex execution is consistent with a largely internally funded, low-leverage approach so far. But it does not yet demonstrate compliance with a stated FY27 leverage ceiling, because no such numeric target was disclosed. The key monitoring point is whether the remaining roughly Rs 1,250 Crores of the FY27 capex plan is funded through operating cash flows or whether project-level borrowing increases materially.

Lead Acid is already a ~12% EBITDA business with a credible path toward 13–14%, whereas New Energy is currently margin-dilutive and is only projected to reach roughly 5–8% operating margins as facilities scale and localization improves. The ARACT ramp therefore creates a near-term consolidated margin drag before any operating leverage emerges.

How to interpret the trajectory

• Lead Acid: The core business is operating near its normalized margin base despite elevated alloy and sulfuric-acid costs. Management’s 13–14% target relies on higher throughput from existing assets, recycling benefits and eventual price recovery rather than a major change in business mix ^[11].
• New Energy: The reported negative segment result in Q1 FY27 shows that the business is still absorbing launch and infrastructure costs. It should not be converted into a formal EBITDA margin because the filing does not define the segment-result line as EBITDA ^[12].
• Steady-state comparison: Even if New Energy reaches the indicated 5–8% operating-margin range, it would remain structurally below Lead Acid’s 12–13% current/normalized profile. The margin case therefore depends more on rapid revenue scaling, utilization and eventual cell/component localization than on immediate margin accretion ^[13].
• Key uncertainty: Management has not provided a single, consolidated EBITDA target or a dated margin curve for the broader New Energy segment. The 5–8% range relates specifically to BESS/pack economics, so it should not be treated as a fully comparable forecast for the entire Li-ion business. Competition is also material: management estimates Indian producers currently face a 15–20% price disadvantage versus Chinese imports ^[9].

Bottom line: ARACT is likely to dilute reported margins during the build-out and early utilization phase. The intended progression is from negative or very low incremental profitability during commissioning toward low-single-digit to high-single-digit operating margins, still below the Lead Acid business. The main trigger for narrowing that gap is utilization and localization—not merely completion of the capex.

ARACT’s disclosed capacity milestones are:

• Customer Qualification Plant: inaugurated on 15 July 2026 as a multi-chemistry, multi-form-factor pilot facility for product optimisation and process validation before scale-up ^[15].
• Giga-cell plant: Phase 1 capacity of 2 GWh is scheduled to commence in Q2 CY2027; total giga-cell capacity is targeted to reach 16 GWh by FY2030 ^[16].
• E+ve plant: commercialization is expected in Q2 FY2027 ^[2].
• BESS giga facility: a 10 GWh facility, with construction commenced, is being developed for energy-storage products serving commercial and industrial as well as grid applications ^{[17] [2]}.

Firm offtake coverage: the investor presentation does not quantify the portion of the 2 GWh Phase 1 capacity covered by firm offtake agreements. Therefore, the percentage is not disclosed and cannot be calculated from the reported information. A news snippet refers to “firm offtake” but provides no contracted GWh or coverage percentage ^[18].